---

Discussion

Ann Tofado:

The announcement is politically striking because it gives the administration a nationwide participation story without requiring Congress to pass a new drug-pricing statute. On September 18, the administration said all 50 states, along with the District of Columbia and Puerto Rico, had applied. But “applied” is doing important work here: CMS, the Centers for Medicare and Medicaid Services, says those applications remain subject to finalization by September 30.

Kate Burvish:

And the mechanism is narrower than the headline may suggest. GENEROUS is a voluntary, five-year CMS model that began in January 2026. A participating manufacturer offers a supplemental rebate to a state Medicaid program. That lowers the drug’s net price; it does not necessarily lower the public list price.

Priya Merlan:

For patients, that distinction matters. The model does not directly reduce ordinary Medicaid copayments. A patient might benefit indirectly if savings help preserve coverage, reduce restrictions, or support other services. But applying to the model does not by itself mean someone will receive a new medicine, face less prior authorization, or pay less at the pharmacy counter.

Red Velhouse:

So nationwide application is not the same as nationwide implementation. Kate, how should we think about the savings claim when Medicaid already gets substantial discounts?

Kate Burvish:

The White House projects $64.3 billion in combined federal and state savings over ten years. That is an administration projection, not an audited result, and the counterfactual is crucial. Medicaid does not generally pay the sticker price. It already receives statutory rebates and state-negotiated supplemental rebates. KFF, a health-policy research organization, estimates those rebates reduced gross Medicaid prescription-drug spending by an average of 53 percent from 2019 through 2024. GENEROUS has to beat the prices states already obtain, not the list price displayed in a press release.

Ann Tofado:

That is also why the political framing is carefully chosen. “Lower prices” is immediately understandable; the incremental discount after existing rebates is much harder to communicate. The administration can claim a broad affordability achievement now, while the details that determine the fiscal result—participating manufacturers, specific drugs, and confidential rebate terms—arrive later or remain unavailable.

Red Velhouse:

But could the model still matter even if the additional discount is smaller than the headline suggests?

Kate Burvish:

Certainly. Medicaid net prescription-drug spending reached $60 billion in 2024, according to CMS, so even a smaller percentage reduction could matter to jointly financed federal and state budgets. Spending is also concentrated: KFF found that the five highest-spending drugs represented about 10 percent of gross Medicaid drug spending in 2024, while the top 50 represented more than one-third. The drug list will determine whether the model has real leverage.

Priya Merlan:

And a lower average price is not the same thing as better health. We would want to know which conditions and populations are affected, whether coverage becomes easier or more restrictive, whether people switch therapies, and whether treatment interruptions change. A model can produce budget savings while creating access problems—or preserve access without producing dramatic savings. Those outcomes have to be measured separately.

Red Velhouse:

Priya, CMS presents standardized coverage criteria as part of the bargain for manufacturers. Why might that improve access, and why might it worry clinicians or patients?

Priya Merlan:

Standardization can reduce a familiar problem: patients and clinicians navigating different rules in different states. If criteria are clinically reasonable and predictable, treatment decisions could become more coherent. But standardization is not automatically generous. If the criteria are restrictive, they can impose the same barrier across participating states, reducing local flexibility rather than expanding access.

Kate Burvish:

That standardization is also an economic trade-off for manufacturers. They may accept a lower Medicaid net price in exchange for more predictable coverage criteria and less need to negotiate separate supplemental rebates state by state. That can reduce administrative costs and uncertainty. But manufacturers will participate only when the commercial and strategic value outweighs the discount they are giving up.

Ann Tofado:

And that voluntary structure is the political hinge. States have applied, but manufacturers still decide whether to enter agreements, and states may decide which participating-manufacturer drugs they actually purchase through the model. The administration gets the appearance of national reach, but implementation remains distributed among federal officials, state programs, managed-care organizations, and drug companies.

Red Velhouse:

Could that structure give CMS meaningful bargaining power, or can manufacturers simply decline and protect their existing arrangements?

Kate Burvish:

Both are possible. A unified framework may make it easier for states to pursue a common benchmark, especially for expensive drugs with large Medicaid use. But the more valuable a drug is to Medicaid programs, the more valuable participation may be to its manufacturer—and the stronger the incentive to negotiate selectively. If high-spending manufacturers stay out, the headline savings could shrink substantially.

Ann Tofado:

There is also a coalition problem. States may welcome savings but already negotiate rebates and must make operational changes, including coordination with managed-care organizations. Manufacturers may oppose lower net prices but value standardized rules. Federal officials want a visible national accomplishment. Those interests overlap enough to launch the model, but not enough to guarantee broad participation or easy implementation.

Priya Merlan:

For patients, participation is not a simple yes-or-no switch. A medicine could be eligible, a manufacturer could participate, and a state could still make choices about coverage or utilization management. The clinically important question is whether people can start and stay on effective treatment. Cost savings that appear in a spreadsheet should not be treated as proof of improved care.

Red Velhouse:

Let’s turn to the international benchmark, because “most favored nation” can sound like the absolute lowest price anywhere. Is that what this model uses?

Kate Burvish:

Not exactly. KFF describes a benchmark based on the second-lowest reported international net price among selected countries, adjusted through a purchasing-power-parity method. It is a technical comparison of net prices, not simply a promise to match the cheapest price found anywhere. That distinction matters because the benchmark determines how large the additional rebate would need to be.

Ann Tofado:

It also shows how political language can outrun administrative design. “Lowest foreign price” is a potent slogan. The actual model depends on country selection, confidential net-price information, and the formula used to adjust those prices. The administration’s message is broad; the governing mechanism is narrower and more conditional.

Red Velhouse:

What could manufacturers do in response beyond simply participating or refusing?

Kate Burvish:

Analysts have identified several possibilities, though none is an established outcome of GENEROUS. Manufacturers might change launch strategies in lower-price countries, adjust international prices, or alter how confidential net prices are reported. They could also reconsider which products enter the model. The broader concern is whether lower public-program prices change incentives for research, investment, or competition—but the direction and size of those effects are unknown.

Ann Tofado:

And the model sits inside a larger argument about who has authority over drug prices. The first Trump administration’s 2020 Medicare most-favored-nation effort was blocked by federal courts and later withdrawn. The current approach is voluntary and focused on Medicaid, which reduces its immediate legal reach. But it may still establish a political precedent for more centralized purchasing.

Priya Merlan:

The legal structure matters clinically because uncertainty can delay implementation or change which medicines are available through the model. The Congressional Research Service identified questions about whether Section 1115A, the authority used for the CMS Innovation Center, can support imposing or expanding most-favored-nation pricing. A voluntary demonstration may reduce that risk, but it does not make every legal or administrative question disappear.

Red Velhouse:

Ann, is this primarily a policy experiment, an election-year accomplishment, or a step toward mandatory pricing?

Ann Tofado:

It is all three possibilities, but not equally certain. Formally, it is a five-year demonstration rather than a permanent change to Medicaid law. It is plainly being presented as an accomplishment ahead of the 2026 midterm elections. And politically, successful implementation could make broader federal bargaining seem more achievable. But that last outcome depends on actual savings, access results, legal durability, and manufacturer behavior.

Kate Burvish:

That is why success should not be defined by the projected $64.3 billion alone. Analysts need to separate savings caused by GENEROUS from changes in enrollment, utilization, drug mix, or ordinary rebate negotiations. The relevant comparison is what Medicaid would have spent on the same treatments under existing arrangements. Without that comparison, a large gross number can obscure a modest incremental effect.

Priya Merlan:

And the patient-level scorecard should include treatment continuity, prior-authorization delays, use of competing medicines, and outcomes in conditions such as cancer, diabetes, and asthma. Those are not merely technical measures. A patient who cannot obtain a medicine on time experiences the policy differently from a budget analyst, even if both are looking at the same drug.

Red Velhouse:

Before the September 30 deadline for finalizing applications, what information would most improve public understanding?

Kate Burvish:

The executed agreements, the participating manufacturers and drugs, the rebate formulas, and a transparent account of how the international benchmark compares with existing Medicaid net prices. Without those details, it is difficult to estimate incremental savings or determine whether the model reaches the medicines driving the most spending.

Ann Tofado:

I would also watch how states and managed-care organizations divide responsibility, and whether standardized criteria are genuinely uniform. The phrase “all 50 states” can conceal very different levels of operational commitment. The political test is whether nationwide application becomes meaningful participation or remains a powerful announcement attached to uneven implementation.

Priya Merlan:

For patients and clinicians, the clearest signals will be practical: which medicines are covered, what authorization rules apply, whether alternatives are substituted, and whether people experience fewer interruptions. Lower net prices are promising for program sustainability, but they are not themselves evidence that care has improved.

Red Velhouse:

The central unresolved issue is whether GENEROUS will produce substantial savings beyond Medicaid’s already deep rebate system—and whether those savings translate into easier, more reliable care rather than simply lower government spending. Watch for finalized applications, manufacturer and drug participation, the actual rebate and benchmark terms, coverage criteria, and evidence about access and treatment continuity. The model’s promise is national, but its consequences will be decided drug by drug and patient by patient. Sources and references for this discussion are
available with the episode at Factolio.com.

---

Sources and References

These sources supported the factual material used in this discussion. Factolio’s panel discussion is AI-generated from researched evidence and is written in original language.

1. The White House — Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs (PRIMARY)
2. Centers for Medicare & Medicaid Services — GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model (PRIMARY)
3. KFF — A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs (ANALYSIS)
4. Centers for Medicare & Medicaid Services — CMS Announces New Drug Payment Model to Strengthen Medicaid and Better Serve Vulnerable Americans (PRIMARY)
5. KFF — Recent Trends in Medicaid Outpatient Prescription Drugs and Spending (DATA)
6. Associated Press — Trump announces all 50 states are joining Medicaid drug pricing model (NEWS)
7. Congressional Research Service — Most-Favored-Nation Prescription Drug Pricing Executive Order: Legal Issues (ANALYSIS)